Skip to main content
Clinical Phytoscience

International Journal of Phytomedicine and Phytotherapy

Table 4 Effect of CRME on Liver function test

From: Promising anitidiabetic potential of Cuscuta reflexa leaves methanol extract in alloxan-induced diabetic rats

Groups

Liver function test

 

ALT (U/l)

ALP(U/l)

AST(U/l)

Bilirubin (mg/dl)

Group I

51.95 ± 2.4

35.50 ± 3.1

105.50 ± 3.9

0.49 ± 0.04

Group II

79.50 ± 3.7a**

87.70 ± 4.1a**

226.45 ± 6.9a**

1.39 ± 0.07a**

Group III

73.15 ± 3.0bη

80.45 ± 4.3bη

195.08 ± 5.4b*

1.28 ± 0.06bη

Group IV

60.55 ± 3.9b*

70.55 ± 4.1b*

135.15 ± 6.6b**

0.75 ± 0.03b**

Group V

55.40 ± 3.3b*

54.80 ± 3.1b**

96.45 ± 4.1b**

0.63 ± 0.04b**

Group VI

49.25 ± 3.7b**

39.35 ± 3.8b**

71.19 ± 3.4b**

0.57 ± 0.02b**

  1. All values were expressed as mean ± S.E.M (n = 3). (*) indicates statistically significant difference from the respective group (**p < 0.01) whereas (η) indicates statistically no significant difference from the respective group (p > 0.05) using ANOVA, followed by Dunnett’s multiple comparison test. a = while compared with healthy control, b = while compared with diabetic control. Group I = Healthy control, Group II = Diabetic control, Group III = Diabetic control + 10 mg/kg of gliclazide, Group IV = Diabetic control + 100 mg/kg CRME, Group V = Diabetic control + 200 mg/kg CRME, Group VI = Diabetic control + 400 mg/kg CRME
Back to article page